Press Releases

Date Title and Summary Additional Formats  
Toggle Summary Karyopharm Announces Preliminary Unaudited Second Quarter Product Sales for XPOVIO® (selinexor)
-- Preliminary Unaudited XPOVIO Net Product Sales of Approximately $18.5 Million for the  Second Quarter 2020 -- -- Strongest Quarterly XPOVIO Sales Since July 2019 Commercial Launch -- NEWTON, Mass. , July 14, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc.
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass. , July 01, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 41,700 shares of
View HTML
Toggle Summary Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 2b SADAL Study Results in The Lancet Haematology
NEWTON, Mass. , June 24, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the results of the Phase 2b SADAL ( S elinexor A gainst D iffuse A ggressive L ymphoma) study evaluating XPOVIO in patients with relapsed
View HTML
Toggle Summary Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
-- XPOVIO is Now the Only Single-Agent, Oral Therapy Approved for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, Including DLBCL Arising from Follicular Lymphoma -- -- XPOVIO is the First and Only FDA-Approved Drug for Use in Both Multiple Myeloma and DLBCL --
View HTML
Toggle Summary Karyopharm Presents XPOVIO® (selinexor) and Eltanexor Data at the European Hematology Association 2020 Virtual Annual Meeting
-- Selinexor Demonstrates a Significant Survival Benefit in Patients with Relapsed or Refractory DLBCL and Durable Responses in Important DLBCL Patient Subgroups, Including Those with Primary Refractory Disease and Regardless of Number of Prior Therapies -- NEWTON, Mass.
View HTML
Toggle Summary Karyopharm Announces Dosing of First Patient in a Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Patients with Newly Diagnosed or Recurrent Glioblastoma
NEWTON, Mass. , June 09, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced dosing of the first patient in a Phase 1/2 clinical study evaluating oral selinexor in combination with standard of care therapy in patients
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass. , June 01, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovation-driven pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 25,800 shares of
View HTML
Toggle Summary Karyopharm Reports Positive Phase 3 BOSTON Data in Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program
-- Combination of Once-Weekly XPOVIO ® (selinexor), Once-Weekly Velcade ® (bortezomib) and Dexamethasone (SVd) Prolonged Median Progression-Free Survival by 47% Compared to Standard Twice-Weekly Velcade ® plus Dexamethasone (Vd) -- -- SVd Was Superior to Vd Across Key Secondary Efficacy Endpoints
View HTML
Toggle Summary Karyopharm to Participate at Jefferies Virtual Healthcare Conference
-- Fireside Chat Scheduled for Tuesday, June 2, 2020 , at 9:30 a.m. ET -- NEWTON, Mass. , May 26, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman , MD, PhD, Chief Executive Officer, will
View HTML
Toggle Summary Karyopharm Announces Investor Conference Call to Discuss Phase 3 BOSTON Data To Be Presented at the American Society of Clinical Oncology 2020 Virtual Scientific Program
-- Conference Call Scheduled for Friday, May 29, 2020 at 1:00 p.m. ET -- NEWTON, Mass. , May 26, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven  pharmaceutical company, today announced it will host an investor conference call to discuss detailed results
View HTML